Evercore ISI lowered the firm’s price target on Fortrea (FTRE) to $14 from $25 and keeps an Outperform rating on the shares. The firm made several price target adjustments and additions to the firm’s Tactical call lists as part of the firm’s healthcare technology and distribution preview for Q1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea Holdings Earnings Call Signals Steady Turnaround
- Fortrea upgraded to Buy from Hold at TD Cowen
- Fortrea: Strengthening Fundamentals, Cost Efficiencies, and Resilient Demand Underpin Buy Rating
- Fortrea Backs GE Healthcare’s New PET Tracer in Completed Phase 1 Study
- Fortrea price target lowered to $14 from $16 at Deutsche Bank